12/18
04:45 am
bntx
BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field
Low
Report
BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field
12/11
07:03 pm
bntx
BioNTech SE (BNTX) is a Buy on Lung Cancer Treatment Prospects: Clear Street [Yahoo! Finance]
Low
Report
BioNTech SE (BNTX) is a Buy on Lung Cancer Treatment Prospects: Clear Street [Yahoo! Finance]
12/11
10:04 am
bntx
BioNTech (NASDAQ:BNTX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
BioNTech (NASDAQ:BNTX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/11
09:18 am
bntx
BioNTech (NASDAQ:BNTX) had its price target raised by analysts at Berenberg Bank from $150.00 to $155.00. They now have a "buy" rating on the stock.
Low
Report
BioNTech (NASDAQ:BNTX) had its price target raised by analysts at Berenberg Bank from $150.00 to $155.00. They now have a "buy" rating on the stock.
12/9
08:10 am
bntx
BioNTech (NASDAQ:BNTX) was upgraded by analysts at UBS Group AG to a "hold" rating.
Low
Report
BioNTech (NASDAQ:BNTX) was upgraded by analysts at UBS Group AG to a "hold" rating.
12/9
07:00 am
bntx
BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer
Low
Report
BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer
12/6
03:30 pm
bntx
BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer
Low
Report
BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer
12/3
04:00 pm
bntx
BioNTech (NASDAQ:BNTX) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc.. They now have a $151.00 price target on the stock.
Low
Report
BioNTech (NASDAQ:BNTX) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc.. They now have a $151.00 price target on the stock.
12/3
09:01 am
bntx
BioNTech Achieves Minimum Condition in CureVac Exchange Offer
Low
Report
BioNTech Achieves Minimum Condition in CureVac Exchange Offer
11/26
07:30 am
bntx
BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration
Low
Report
BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration
11/25
09:19 am
bntx
BioNTech (NASDAQ:BNTX) had its "buy" rating reaffirmed by analysts at Berenberg Bank.
Low
Report
BioNTech (NASDAQ:BNTX) had its "buy" rating reaffirmed by analysts at Berenberg Bank.
11/17
09:18 am
bntx
BioNTech (NASDAQ:BNTX) had its "buy" rating reaffirmed by analysts at Berenberg Bank.
Low
Report
BioNTech (NASDAQ:BNTX) had its "buy" rating reaffirmed by analysts at Berenberg Bank.
11/12
09:23 am
bntx
BioNTech (NASDAQ:BNTX) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Low
Report
BioNTech (NASDAQ:BNTX) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
11/10
08:03 am
bntx
BioNTech (NASDAQ:BNTX) had its price target raised by analysts at HC Wainwright from $136.00 to $140.00. They now have a "buy" rating on the stock.
Low
Report
BioNTech (NASDAQ:BNTX) had its price target raised by analysts at HC Wainwright from $136.00 to $140.00. They now have a "buy" rating on the stock.
11/6
09:20 am
bntx
BioNTech (NASDAQ:BNTX) had its price target raised by analysts at UBS Group AG from $115.00 to $117.00. They now have a "neutral" rating on the stock.
Low
Report
BioNTech (NASDAQ:BNTX) had its price target raised by analysts at UBS Group AG from $115.00 to $117.00. They now have a "neutral" rating on the stock.
11/4
09:21 am
bntx
BioNTech (NASDAQ:BNTX) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Low
Report
BioNTech (NASDAQ:BNTX) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
11/3
05:03 pm
bntx
BioNTech (NASDAQ:BNTX) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Low
Report
BioNTech (NASDAQ:BNTX) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
11/3
05:03 pm
bntx
BioNTech (NASDAQ:BNTX) had its "hold" rating reaffirmed by analysts at Cowen Inc.
Low
Report
BioNTech (NASDAQ:BNTX) had its "hold" rating reaffirmed by analysts at Cowen Inc.
11/3
06:45 am
bntx
BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update
Low
Report
BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update
10/30
08:12 pm
bntx
Singapore Approves Latest Pfizer/BioNTech COVID-19 Vaccine for All Ages [Yahoo! Finance]
Low
Report
Singapore Approves Latest Pfizer/BioNTech COVID-19 Vaccine for All Ages [Yahoo! Finance]
10/28
07:45 am
bntx
BioNTech to Host Innovation Series R&D Day on November 11, 2025
Low
Report
BioNTech to Host Innovation Series R&D Day on November 11, 2025
10/27
07:45 am
bntx
BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025
Low
Report
BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025
10/24
05:33 am
bntx
Pfizer and BioNTech Receive Health Sciences Authority Approval for SARS-CoV-2 Sublineage LP.8.1-Adapted Monovalent COVID-19 Vaccine in Singapore
Low
Report
Pfizer and BioNTech Receive Health Sciences Authority Approval for SARS-CoV-2 Sublineage LP.8.1-Adapted Monovalent COVID-19 Vaccine in Singapore
10/24
05:10 am
bntx
Pfizer and BioNTech Receive Health Sciences Authority Approval for SARS-CoV-2 Sublineage LP.8.1-Adapted Monovalent COVID-19 Vaccine in Singapore
Low
Report
Pfizer and BioNTech Receive Health Sciences Authority Approval for SARS-CoV-2 Sublineage LP.8.1-Adapted Monovalent COVID-19 Vaccine in Singapore
10/23
12:32 pm
bntx
BioNTech (NASDAQ:BNTX) had its price target lowered by analysts at JPMorgan Chase & Co. from $121.00 to $120.00. They now have a "neutral" rating on the stock.
Low
Report
BioNTech (NASDAQ:BNTX) had its price target lowered by analysts at JPMorgan Chase & Co. from $121.00 to $120.00. They now have a "neutral" rating on the stock.